The virtual R&D day will feature a panel discussion with Key Opinion Leaders (KOLs) in oncology Ezra Cohen, MD, FRCPSC, FASCO (San Diego Center for Precision Immunotherapy), Perry Nisen, MD, PhD (CEO and Executive Chairman of Quanta), and with Les Tari, PhD (Cidara’s Chief Scientific Officer). The discussion will be focused on Cidara’s Cloudbreak® platform which couples potent inhibitors to a human antibody fragment to create highly potent, long-acting drug-Fc conjugates (DFCs) designed to simultaneously inhibit multiple disease targets.

Cidara has been developing Cloudbreak since 2018 and entered into a platform-validating collaboration agreement with Janssen Pharmaceuticals, Inc. in April 2021 for the development of CD388, currently in Phase 1 studies, for the universal prevention and treatment of influenza.

The panel will highlight the principles behind the Cloudbreak DFC approach, contrast it with ADCs, mAbs and small molecule applications and will review the potential advantages of DFCs in oncology.  New data emerging from Cidara’s SARS-CoV-2 and oncology DFC program in the immune checkpoint blockade pathway will be featured.

A question-and-answer session will follow.